Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Tysabri label update: liver injury

    • 8 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Biogen Idec Inc, Elan Pharmaceuticals Inc.Important safety information - TYSABRI (Rm) (natalizumab). Internet Document: [2 pages], Feb 2008. Available from: URL: http://www.fda.gov

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Tysabri label update: liver injury. React. Wkly. 1192, 2 (2008). https://doi.org/10.2165/00128415-200811920-00002

    Download citation

    Keywords

    • Public Health
    • Bilirubin
    • Liver Injury
    • Healthcare Professional
    • Causative Agent